Text Size

Optimized Scheme About Antiplatelet Therapy in Patients With Coronary Heart Disease (Sacred)

This study is not yet open for participant recruitment.
Verified November 2012 by Shenyang Northern Hospital
Sponsor:
Collaborator:
Guangdong General Hospital
Information provided by (Responsible Party):
Yaling Han, Shenyang Northern Hospital
ClinicalTrials.gov Identifier:
NCT01735305
First received: November 12, 2012
Last updated: November 27, 2012
Last verified: November 2012
History of Changes
  Purpose

The investigators designed a clinical randomized trials,which established a registration platform of antiplatelet therapy in patients with coronary heart disease,in order to understand current situation of antithrombotic treatment in our country at present stage,and to evaluate the popularity rate of antiplatelet therapy which is followed domestic and international relevant guidelines in our country,finally analyse events risk factors of blood clot and bleeding after antiplatelet therapy in patients with coronary heart disease.


Condition
Coronary Artery Disease

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Study of Optimized Scheme About Antiplatelet Therapy in Patients With Coronary Heart Disease

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Shenyang Northern Hospital:

Primary Outcome Measures:
  • death [ Time Frame: 12month ] [ Designated as safety issue: Yes ]
    Cardiovascular death Non cardiovascular death Unexplained death


Secondary Outcome Measures:
  • Cardiovascular events [ Time Frame: 12month ] [ Designated as safety issue: No ]
    Lethal myocardial infarction PTCA or CABG hemorrhage Deadly stroke


Estimated Enrollment: 8000
Study Start Date: November 2012
Estimated Study Completion Date: July 2014
Estimated Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)
Groups/Cohorts
Positive group
The groups who Clinical events happened
Negative Group
The groups who Clinical events have not happened

  Eligibility

Ages Eligible for Study:   18 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Patient of coronary heart disease

Criteria

Inclusion criteria:

  1. Clinical diagnosis of coronary heart disease
  2. Age should be full of 18 years old
  3. Have been taking anti-platelet drugs
  4. Informed consent signed

Exclusion Criteria:

  1. With severe disease and life expectancy 6 months or less
  2. The researchers think follow-up more difficult situation (travel, speech or mental disorder, etc.)
  3. Taking part in an intervening clinical research
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01735305

Contacts
Contact: Yaling Han, MD +86-24-23922184 13998847715@qq.com

Locations
China, Guangdong
Guangdong General Hospital Not yet recruiting
Guangzhou, Guangdong, China
Contact: Jiyan Chen, MD     15920520902        
China, Liaoning
Northern Hospital Not yet recruiting
Shenyang, Liaoning, China
Contact: Yaling Han, Dr     +86-24-23922184     hanyal@263.net    
Sponsors and Collaborators
Shenyang Northern Hospital
Guangdong General Hospital
Investigators
Principal Investigator: Yaling Han, MD Shenyang Northern Hospital
  More Information

No publications provided

Responsible Party: Yaling Han, Head of Cardiology, Shenyang Northern Hospital
ClinicalTrials.gov Identifier: NCT01735305     History of Changes
Other Study ID Numbers: SYNH-20121113
Study First Received: November 12, 2012
Last Updated: November 27, 2012
Health Authority: China: Ministry of Health

Keywords provided by Shenyang Northern Hospital:
Coronary Artery Disease
antiplatelet therapy

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
 Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases

ClinicalTrials.gov processed this record on June 18, 2013